Press release

Insmed to Host Second-Quarter 2023 Financial Results Conference Call on Thursday, August 3, 2023

BRIDGEWATER, N.J., July 20, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of

articleInsmed IncorporatedJuly 20, 20233/company/insmed-inc/news/insmed-to-host-second-quarter-2023-financial-results-conference-call-on-thursday
Insmed to Host Second-Quarter 2023 Financial Results Conference Call on Thursday, August 3, 2023

About this update from Insmed Incorporated

[{"type":"text","content":"BRIDGEWATER, N.J., July 20, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its second-quarter 2023 financial results on Thursday, August 3, 2023.\nInsmed management will host a conference call for investors beginning at 8:30 a.m. ET on Thursday, August 3, 2023, to discuss the financial results and provide a business update.\nShareholders and other interested parties may participate in the conference call by dialing (646) 960-0278 (U.S. and international) and referencing access code 7862189. The call will also be webcast live on the company's website at www.insmed.com.\nA replay of the conference call will be accessible approximately 1 hour after its completion through September 3, 2023, by dialing (647) 362-9199 (U.S. and international) and referencing access code 7862189. A webcast of the call will also be archived for 90 days under the Investor Relations section of the company's website at www.insmed.com.\nAbout Insmed\nInsmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a footprint across Europe and in Japan. For more information, visit www.insmed.com.\nContact:\nInvestors:\nBryan DunnExecutive Director, Investor RelationsInsmed(646) [email protected]\nEleanor BarisserAssociate Director, Investor RelationsInsmed(718) [email protected]\nMedia:\nMandy FaheyExecutive Director, Corporate CommunicationsInsmed(732) [email protected]\n\n \n\n\n\n View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-to-host-second-quarter-2023-financial-results-conference-call-on-thursday-august-3-2023-301881491.html\nSOURCE Insmed Incorporated","length":5203,"tagName":"div"}]

More updates from Insmed Incorporated